Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Hepatitis C, Chronic 1Conjunctival Intraepithelial Neoplasia 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 9gadolinium ethoxybenzyl DTPA 4Hepatectomy 4lenvatinib 3entecavir 3Sufentanil 3Ribavirin 3Propranolol 3Lamivudine 3sofosbuvir-velpatasvir drug combination 2peginterferon alfa-2a 2gadoterate meglumine 2atezolizumab 2Thrombectomy 2Tenofovir 2Sevoflurane 2Radiofrequency Ablation 2Laparoscopy 2Esketamine 2Chemoembolization, Therapeutic 2Bevacizumab 2xihuang 1stronger neominophagen C 1ledipasvir 1huaier 1halofantrine 1gadoteridol 1gadodiamide 1gadobutrol 1gadobenic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Carcinoma, Hepatocellular × Introns × Clear all
NCT00375661 2015-09-02

Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC

Kyoto University Hospital

Phase 4 Completed
100 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡